web analytics
18.3 C
Munich
Friday, June 18, 2021

Current, AcnEase; the Rise of Herborium Group, Inc. (OTCMKTS: HBRM)

Herborium Group, Inc. (OTCMKTS: HBRM) is moving up the charts in recent weeks as the Company is becoming current on OTCMarkets with the recent filing of a number of quarters including for the period ending August 31, 2020. The stock is quickly attracting a fast growing shareholder base who continues to heavily accumulate.

HBRM is making money off its acne product AcnEase recently reporting a net income in the past 3 quarters with revenues of $260,000 for the 3 months ended August 31, 2020. The Company has very little debt and no big notes on the books and states on its website its longer-term pipeline includes arthritis candidate and the anti-infectious product candidate focused on antibiotic resistant infections. The Company has a strong team behind it and is led by its founder, high level biotech exec Agnes Olszewski, PhD, founding partner of ClearSign Diagnostics (CSD) and holding 66,7% preferred A shares of HBRM. Other founding partner CSD James Gilligan holds 33,3% pref A of HRBM and is also co founder of Osteon therapeutics.

Herborium Group, Inc. (OTCMKTS: HBRM) is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billon in the USA and UK alone.

This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies, Herborium introduces its own botanical therapeutics® defined as “bridge products”, an emerging category of natural medicines whose safety and efficacy are validated through clinical studies.

Botanical Therapeutics® represents benefits and attributes of both aforementioned traditional sectors. Botanical Therapeutics bring the intellectual property value, posology, clinical validation and rapid market entry while maintaining a safety profile of botanical ingredients and offering the benefits of preventive medicine and cost containment. For its own Botanical Therapeutics the Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its proprietary therapeutic candidates from Traditional Chinese Medicine with initial confirmatory data and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. This strategy serves to mitigate risk in the product development and marketing strategies.

To Find out the inside Scoop on HBRM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HBRM

The Company secured a pipeline of botanical ingredient based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women’s Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. The longer-term pipeline includes arthritis candidate and the anti-infectious product candidate focused on antibiotic resistant infections. Herborium Managements represents a unique blend of expertise with over 50 years of successful business dealings in Asia, an exceptional track record in pharmacology and drug development, clinical testing and regulatory affairs in the US and Europe, supported by high standards, know how in herbal science and formulation, and specifically Modern Chinese Medicine.

Herborium presently sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. With initial seed investment brought to the Company by Friends and Family and a small professional round, spear-headed by Southridge Investment Group LLC, the Company is ideally positioned for exponential growth in the near future. Down economic times are actually realizing an additional pressure on the sector, and both consumers and insurance companies look for safer and more affordable healthcare options

Since commencing  sales  of  its  principal  product,  AcnEase,  the  Company  has purchased all  of  the  product sold, and held in inventory from AH USA, a USA -based business entity owned by the individual who is the inventor and sole owner of AcnEase,  an acne product.  The Company is party to a licensing agreement with AH USA under which the Company, as licensee, is the exclusive worldwide distributor of AcnEase. The CEO of HBRM is founding partner of ClearSign Diagnostics (CSD) and holding 66,7% preferred A shares of HBRM. Other founding partner CSD James Gilligan holds 33,3% pref A of HRBM and is also co founder of Osteon therapeutics.

For more on HBRM Subscribe Right Now!

HBRM is moving up the charts in recent weeks as the Company is becoming current on OTCMarkets with the recent filing of a number of quarters including for the period ending August 31, 2020. The stock is quickly attracting a fast growing shareholder base who continues to heavily accumulate. HBRM is making money off its acne product AcnEase recently reporting a net income in the past 3 quarters with revenues of $260,000 for the 3 months ended August 31, 2020. The Company has very little debt and no big notes on the books and states on its website its longer-term pipeline includes arthritis candidate and the anti-infectious product candidate focused on antibiotic resistant infections. The Company has a strong team behind it and is led by its founder, high level biotech exec Agnes Olszewski, PhD, founding partner of ClearSign Diagnostics (CSD) and holding 66,7% preferred A shares of HBRM. Other founding partner CSD James Gilligan holds 33,3% pref A of HRBM and is also co founder of Osteon therapeutics. We will be updating on HBRM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HBRM.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in HBRM either long or short and we have not been compensated for this article.

 

 

 

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.